Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
13 May 2021
Historique:
received: 06 04 2021
revised: 02 05 2021
accepted: 11 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 9 6 2021
Statut: epublish

Résumé

Since the outbreak of coronavirus disease 2019 (COVID-19), many put their hopes in the rapid availability of effective immunizations. Human milk, containing antibodies against syndrome coronavirus 2 (SARS-CoV-2), may serve as means of protection through passive immunization. We aimed to determine the presence and pseudovirus neutralization capacity of SARS-CoV-2 specific IgA in human milk of mothers who recovered from COVID-19, and the effect of pasteurization on these antibodies. This prospective case control study included lactating mothers, recovered from (suspected) COVID-19 and healthy controls. Human milk and serum samples were collected. To assess the presence of SARS-CoV-2 antibodies we used multiple complementary assays, namely ELISA with the SARS-CoV-2 spike protein (specific for IgA and IgG), receptor binding domain (RBD) and nucleocapsid (N) protein for IgG in serum, and bridging ELISA with the SARS-CoV-2 RBD and N protein for specific Ig (IgG, IgM and IgA in human milk and serum). To assess the effect of pasteurization, human milk was exposed to Holder (HoP) and High Pressure Pasteurization (HPP). Human milk contained abundant SARS-CoV-2 antibodies in 83% of the proven cases and in 67% of the suspected cases. Unpasteurized milk with and without these antibodies was found to be capable of neutralizing a pseudovirus of SARS-CoV-2 in (97% and 85% of the samples respectively). After pasteurization, total IgA antibody levels were affected by HoP, while SARS-CoV-2 specific antibody levels were affected by HPP. Pseudovirus neutralizing capacity of the human milk samples was only retained with the HPP approach. No correlation was observed between milk antibody levels and neutralization capacity. Human milk from recovered COVID-19-infected mothers contains SARS-CoV-2 specific antibodies which maintained neutralization capacity after HPP. All together this may represent a safe and effective immunization strategy after HPP.

Sections du résumé

BACKGROUND BACKGROUND
Since the outbreak of coronavirus disease 2019 (COVID-19), many put their hopes in the rapid availability of effective immunizations. Human milk, containing antibodies against syndrome coronavirus 2 (SARS-CoV-2), may serve as means of protection through passive immunization. We aimed to determine the presence and pseudovirus neutralization capacity of SARS-CoV-2 specific IgA in human milk of mothers who recovered from COVID-19, and the effect of pasteurization on these antibodies.
METHODS METHODS
This prospective case control study included lactating mothers, recovered from (suspected) COVID-19 and healthy controls. Human milk and serum samples were collected. To assess the presence of SARS-CoV-2 antibodies we used multiple complementary assays, namely ELISA with the SARS-CoV-2 spike protein (specific for IgA and IgG), receptor binding domain (RBD) and nucleocapsid (N) protein for IgG in serum, and bridging ELISA with the SARS-CoV-2 RBD and N protein for specific Ig (IgG, IgM and IgA in human milk and serum). To assess the effect of pasteurization, human milk was exposed to Holder (HoP) and High Pressure Pasteurization (HPP).
RESULTS RESULTS
Human milk contained abundant SARS-CoV-2 antibodies in 83% of the proven cases and in 67% of the suspected cases. Unpasteurized milk with and without these antibodies was found to be capable of neutralizing a pseudovirus of SARS-CoV-2 in (97% and 85% of the samples respectively). After pasteurization, total IgA antibody levels were affected by HoP, while SARS-CoV-2 specific antibody levels were affected by HPP. Pseudovirus neutralizing capacity of the human milk samples was only retained with the HPP approach. No correlation was observed between milk antibody levels and neutralization capacity.
CONCLUSIONS CONCLUSIONS
Human milk from recovered COVID-19-infected mothers contains SARS-CoV-2 specific antibodies which maintained neutralization capacity after HPP. All together this may represent a safe and effective immunization strategy after HPP.

Identifiants

pubmed: 34068142
pii: nu13051645
doi: 10.3390/nu13051645
pmc: PMC8152997
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Stichting Steun Emma
ID : NA

Références

Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
J Pediatr. 1977 Jan;90(1):29-35
pubmed: 318682
J Food Prot. 2008 Jan;71(1):109-18
pubmed: 18236670
Ann Allergy Asthma Immunol. 1998 Dec;81(6):523-33; quiz 533-4, 537
pubmed: 9892025
Int J Food Microbiol. 2020 Jul 16;325:108629
pubmed: 32325344
Lancet. 2020 Jun 6;395(10239):1751-1752
pubmed: 32505245
J Virol. 2004 Jan;78(2):947-57
pubmed: 14694126
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
J Pediatr Gastroenterol Nutr. 2009 Jul;49(1):112-25
pubmed: 19502997
Food Chem. 2014 May 15;151:79-85
pubmed: 24423505
Signal Transduct Target Ther. 2020 Nov 24;5(1):275
pubmed: 33235188
J Matern Fetal Neonatal Med. 2010 Sep;23 Suppl 2:1-20
pubmed: 20840052
Nutrients. 2019 Apr 24;11(4):
pubmed: 31022910
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Vaccine. 2003 Jul 28;21(24):3374-6
pubmed: 12850343
PLoS One. 2013 Aug 14;8(8):e70867
pubmed: 23967126
Acta Pharm Sin B. 2020 Jul;10(7):1228-1238
pubmed: 32363136
Nutrients. 2019 May 24;11(5):
pubmed: 31137691
Nutrients. 2016 Aug 02;8(8):
pubmed: 27490567
J Immunol. 2020 Dec 15;205(12):3491-3499
pubmed: 33127820
Lancet Child Adolesc Health. 2020 May;4(5):355
pubmed: 32246910
Pediatrics. 2006 Feb;117(2):425-32
pubmed: 16452362
Nutrients. 2019 Jul 11;11(7):
pubmed: 31336756
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Mucosal Immunol. 2011 Nov;4(6):603-11
pubmed: 21975936
iScience. 2020 Nov 20;23(11):101735
pubmed: 33134887

Auteurs

Britt J van Keulen (BJ)

Department of Pediatrics, Amsterdam UMC, Vrije Universiteit, University of Amsterdam Emma Children's Hospital, 1105 AZ Amsterdam, The Netherlands.

Michelle Romijn (M)

Department of Pediatrics, Amsterdam UMC, Vrije Universiteit, University of Amsterdam Emma Children's Hospital, 1105 AZ Amsterdam, The Netherlands.

Albert Bondt (A)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, 3584 CH Utrecht, The Netherlands.
Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.

Kelly A Dingess (KA)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, 3584 CH Utrecht, The Netherlands.
Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.

Eva Kontopodi (E)

Department of Pediatrics, Amsterdam UMC, Vrije Universiteit, University of Amsterdam Emma Children's Hospital, 1105 AZ Amsterdam, The Netherlands.
Food Quality & Design Group, Wageningen University and Research, 6708 WG Wageningen, The Netherlands.

Karlijn van der Straten (K)

Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Maurits A den Boer (MA)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, 3584 CH Utrecht, The Netherlands.
Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.

Judith A Burger (JA)

Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Meliawati Poniman (M)

Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Berend J Bosch (BJ)

Division Infectious Diseases & Immunology/Laboratory of Virology, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 CL Utrecht, The Netherlands.

Philip J M Brouwer (PJM)

Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Christianne J M de Groot (CJM)

Department of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.

Max Hoek (M)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, 3584 CH Utrecht, The Netherlands.

Wentao Li (W)

Division Infectious Diseases & Immunology/Laboratory of Virology, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 CL Utrecht, The Netherlands.

Dasja Pajkrt (D)

Department of Pediatrics, Amsterdam UMC, Vrije Universiteit, University of Amsterdam Emma Children's Hospital, 1105 AZ Amsterdam, The Netherlands.

Rogier W Sanders (RW)

Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Department of Microbiology and Immunolgy, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10065, USA.

Anne Schoonderwoerd (A)

Department of Pediatrics, Amsterdam UMC, Vrije Universiteit, University of Amsterdam Emma Children's Hospital, 1105 AZ Amsterdam, The Netherlands.

Sem Tamara (S)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, 3584 CH Utrecht, The Netherlands.
Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.

Rian A H Timmermans (RAH)

Wageningen Food & Biobased Research, Wageningen University and Research, P.O. Box 17, 6700 AA Wageningen, The Netherlands.

Gestur Vidarsson (G)

Department of Experimental Immunohematology, Sanquin Research, Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, P.O. Box 9190, 1006 AD Amsterdam, The Netherlands.

Koert J Stittelaar (KJ)

Viroclinics Xplore, Viroclinics Biosciences B.V., Nistelrooise Baan 3, 5374 RE Schaijk, The Netherlands.

Theo T Rispens (TT)

Department of Immunopathology, Sanquin Research & Landsteiner Laboratory Academic Medical Centre, 1081 HV Amsterdam, The Netherlands.

Kasper A Hettinga (KA)

Food Quality & Design Group, Wageningen University and Research, 6708 WG Wageningen, The Netherlands.

Marit J van Gils (MJ)

Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Albert J R Heck (AJR)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, 3584 CH Utrecht, The Netherlands.
Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.

Johannes B van Goudoever (JB)

Department of Pediatrics, Amsterdam UMC, Vrije Universiteit, University of Amsterdam Emma Children's Hospital, 1105 AZ Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH